Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Updates from a Phase I clinical trial examining ublituximab in combination with TGR-1202

Owen O'Connor • 9 Jun 2016
EHA 2016
B-Cell Lymphoma Non-Hodgkin Lymphoma

Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY outlines his presentation on the updates from the Phase I clinical trial examining ublituximab in combination with TGR-1202 for non-Hodgkin lymphoma (NCT02006485). Current results confirmed that the drug is well-tolerated and has a highly favorable safety profile and a continued demonstration of good efficacy in patients with indolent lymphoma, as well as patients with diffuse large B-cell lymphoma (DLBCL). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark

More from Owen O'Connor

6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals